Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
• * Siewert's class II or III disease
• Measurable disease
• * At least 1 unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
• No history of known or active brain metastases or primary brain tumors
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• Karnofsky 60-100% OR
• ECOG 0-2
• Life expectancy
• Not specified
• Hematopoietic
• WBC at least 3,000/mm\^3
• Absolute neutrophil count at least 1,000/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic
• Bilirubin no greater than 1.5 mg/dL
• AST and ALT no greater than 3 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)
• Renal
• Creatinine no greater than 1.5 mg/dL
• Cardiovascular
• No prior cerebrovascular event
• No prior orthostatic hypotension
• No myocardial infarction within the past 6 months
• No peripheral vascular disease requiring surgical management
• No evidence of acute ischemia or significant conduction abnormality by EKG
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for at least 2 months after study participation
• No evidence of peripheral neuropathy
• No prior allergic reaction attributed to compounds of similar chemical or biological composition to bortezomib
• No other malignancy within the past 3 years except basal cell skin cancer, carcinoma in situ of the cervix, or adequately treated nonmetastatic prostate cancer
• No ongoing or active infection
• No psychiatric illness or social situation that would preclude study participation
• No other concurrent uncontrolled illness that would preclude study participation
• No other medical condition or reason that would preclude study participation
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• More than 3 weeks since prior immunotherapy
• No concurrent biological or immunological agents
• Chemotherapy
• No more than 1 prior chemotherapy regimen (including adjuvant chemotherapy)
• More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• No concurrent chemotherapy
• Endocrine therapy
• Not specified
• Radiotherapy
• More than 3 weeks since prior radiotherapy
• No concurrent radiotherapy
• Surgery
• Not specified
• Other
• Recovered from all prior therapy
• No other concurrent investigational agents
• No other concurrent anticancer agent or therapy